Condition: Parkinson’s disease


Key Inclusion Criteria:

  • 50-85 years old
  • Diagnosis of idiopathic Parkinson’s disease (PD), with bradykinesia plus one of the other cardinal signs of PD, without any other known or suspected cause of parkinsonism
  • Body weight ranging from 45-110 kg (99-242 lbs) and a body mass index of 18-34 kg/m2

Key Exclusion Criteria:

  • Medical history indicating a Parkinsonian syndrome other than idiopathic PD
  • Known carriers of PD gene mutations
  • History of PD-related freezing episodes or falls

Study Name

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Intravenous Prasinezumab In Participants With Early Parkinson's Disease (IRB no. 00001346)


The purpose of this study is to compare the effects of an experimental drug called prasinezumab in patients with early Parkinson's disease who are taking standard medication (either rasagiline, selegiline, or levodopa) to manage their disease symptoms. Participants will be randomly assigned to receive either prasinezumab or placebo (inactive substance).

Prasinezumab is a type of medication called a monoclonal antibody. Prasinezumab may clear away harmful forms of a specific protein to prevent damage to brain cells, potentially slowing the course of Parkinson’s disease.

Principal Investigator